Information Provided By:
Fly News Breaks for August 8, 2019
AERI
Aug 8, 2019 | 09:14 EDT
Needham analyst Serge Belanger lowered his price target on Aerie Pharma to $54 after its Q2 results and a cut in its FY19 revenue guidance, driven by the shallower than expected launch of Rhopressa and Rocklatan. The analyst keeps his Buy rating on the stock however, saying its reset guidance looks more "achievable", even though he still awaits a better Rocklatan uptake that is suffering from a lack of Managed Care coverage and patient "churning".
News For AERI From the Last 2 Days
There are no results for your query AERI